According to filings with the U.S. Securities and Exchange Commission, Organicell Regenerative Medicine is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Ian Bothwell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Organicell Regenerative Medicine
The Next Generation of Biologic Medicine. Organicell is the leading, fully integrated Exosome Therapeutics Company. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicine. We believe that or ground-breaking research in the field of nanotechnology, specifically exosomes and other micro vesicles, is the next frontier of stem cell-based therapeutics. Organicell is committed to creating life changing and lifesaving therapies for patients. Our mission is to transform regenerative medicine by continuing to combine exosome technology with other synergistic therapies and become the healthcare technology incubator for biologic medicine.

To learn more about Organicell Regenerative Medicine, visit http://organicell.com/

Contact:
Ian Bothwell, Chief Financial Officer
888-963-7881

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.